Depomed Inc. said it changed its name to Assertio Therapeutics Inc. following shareholder approval.

In connection with the name change, Depomed's shares will trade on the Nasdaq Global Select Market under the new symbol ASRT beginning Aug. 15.

According to the company, the Assertio name reflects its renewed commitment to the advancement of patient care in the core areas of neurology, orphan and specialty medicines.

Depomed also completed the relocation of its corporate headquarters from Newark, Calif., to Lake Forest, Ill.